Literature DB >> 24096781

Progress in compliance research and intervention: a commentary.

Robert Rosenheck1.   

Abstract

Year:  2013        PMID： 24096781      PMCID： PMC3799246          DOI： 10.1002/wps.20062

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  17 in total

1.  How do clinical trial participants compare to other patients with schizophrenia?

Authors:  Paul G Barnett; Jennifer Y Scott; Robert A Rosenheck
Journal:  Schizophr Res       Date:  2011-04-22       Impact factor: 4.939

Review 2.  Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.

Authors:  Paolo Fusar-Poli; Matthew J Kempton; Robert A Rosenheck
Journal:  Int Clin Psychopharmacol       Date:  2013-03       Impact factor: 1.659

3.  Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.

Authors:  Wolfgang Gaebel; Andreas Schreiner; Paul Bergmans; Rosario de Arce; Frédéric Rouillon; Joachim Cordes; Lars Eriksson; Enrico Smeraldi
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

4.  Long-acting risperidone and oral antipsychotics in unstable schizophrenia.

Authors:  Robert A Rosenheck; John H Krystal; Robert Lew; Paul G Barnett; Louis Fiore; Danielle Valley; Soe Soe Thwin; Julia E Vertrees; Matthew H Liang
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

5.  A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia.

Authors:  Wayne Macfadden; Yi-Wen Ma; J Thomas Haskins; Cynthia A Bossie; Larry Alphs
Journal:  Psychiatry (Edgmont)       Date:  2010-11

6.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

7.  Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients.

Authors:  David M Taylor; Corina L Young; Shubhra Mace; Maxine X Patel
Journal:  J Clin Psychiatry       Date:  2004-08       Impact factor: 4.384

8.  Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.

Authors:  Somaia Mohamed; Robert Rosenheck; Ilan Harpaz-Rotem; Douglas Leslie; Michael J Sernyak
Journal:  Psychiatr Q       Date:  2009-09-19

9.  Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

Authors:  Nicholas A Keks; Michael Ingham; Akbar Khan; Keith Karcher
Journal:  Br J Psychiatry       Date:  2007-08       Impact factor: 9.319

10.  Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.

Authors:  Sarah M Leatherman; Matthew H Liang; John H Krystal; Robert A Lew; Danielle Valley; Soe Soe Thwin; Robert A Rosenheck
Journal:  J Nerv Ment Dis       Date:  2014-01       Impact factor: 2.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.